Nanoemulsion based concomitant delivery of curcumin and etoposide: Impact on cross talk between prostate cancer cells and osteoblast during metastasis

Journal of Biomedical Nanotechnology

Volumn 10, Issue 11, 2014, Pages 3381-3391

  Shukla, Prashant ^a   Mathur, Vineet ^b   Kumar, Amit ^a   Khedgikar, Vikram ^a   Teja, B Venkatesh ^a   Chaudhary, Dharmendra ^a   Kushwaha, Priyanka ^a   Bora, Himangsu K ^a   Konwar, Rituraj ^a   Trivedi, Ritu ^a   Mishra, Prabhat Ranjan ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b National Institute for Pharmaceutical Education and Research   (India)

Author keywords

Chemoprotective; Combination therapy; Curcumin; Etoposide; HEK 293 (Human Embryonic Kidney Cells); Multidrug resistance; Nanoemulsions; PC3 prostate cancer cells

Indexed keywords

CROSSTALK; CYTOLOGY; DATA ENCAPSULATION; DISEASES; ENZYME INHIBITION; PHARMACOKINETICS;

CHEMOPROTECTIVE; COMBINATION THERAPY; CURCUMIN; ETOPOSIDE; HUMAN EMBRYONIC KIDNEY CELLS; MULTIDRUG RESISTANCE; NANO-EMULSIONS; PROSTATE CANCER CELLS;

OSTEOBLASTS;

CURCUMIN; ETOPOSIDE; ANTINEOPLASTIC AGENT; DRUG COMBINATION; EMULSION; NANOCAPSULE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; ENCAPSULATION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NANOEMULSION; NONHUMAN; OSTEOBLAST; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RAT; SIGNAL TRANSDUCTION; ZETA POTENTIAL; ANIMAL; BONE NEOPLASMS; CELL COMMUNICATION; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; EMULSION; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CURCUMIN; DRUG COMBINATIONS; EMULSIONS; ETOPOSIDE; HUMANS; MALE; MICE; NANOCAPSULES; OSTEOBLASTS; PROSTATIC NEOPLASMS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84904876560     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1912     Document Type: Article

References (36)

1. R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA: A cancer. Journal for Clinicians 63, 11 (2013).
2. J. P. van Brussel, G. J. van Steenbrugge, J. C. Romijn, F. H. Schroder, and G. H. Mickisch, Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur. J. Cancer 35, 664 (1999).
3. C. Bock and T. Lengauer, Managing drug resistance in cancer: lessons from HIV therapy. Nat. Rev. Cancer 12, 494 (2012).
4. L. H. Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra, and R. R. Murthy, Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. The AAPS Journal 6, 55 (2004).
5. Y. Surh, Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 428, 305 (1999).
6. L. D. Guo, X. J. Chen, Y. H. Hu, Z. J. Yu, D. Wang, and J. Z. Liu, Curcumin inhibits proliferation and induces apoptosis of human colorectal cancer cells by activating the mitochondria apoptotic pathway. Phytother. Res. 27, 422 (2013).
7. A. Cort, M. Timur, E. Ozdemir, E. Kucuksayan, and T. Ozben, Synergistic anticancer activity of curcumin and bleomycin: An in vitro study using human malignant testicular germ cells. Mol. Med. Report 5, 1481 (2012).
8. D. Singodia, S. Kansal, A. Verma, R. Shukla, P. Shukla, P. Dwivedi, V. Kumar, P. Gupta, A. Dwivedi, and P. R. Mishra, Development of nevirapine loaded novel surfactant free polymeric emulsion and investigations for its suitability as drug delivery vehicle. Journal of Bionanoscience 4, 66 (2010).
9. P. Shukla, G. Gupta, D. Singodia, R. Shukla, A. K. Verma, P. Dwivedi, S. Kansal, and P. R. Mishra, Emerging trend in nanoengineered polyelectrolyte-based surrogate carriers for delivery of bioactives. Expert Opinion on Drug Delivery 7, 993 (2010).
10. M. Ukawala, T. Rajyaguru, K. Chaudhari, A. Manjappa, S. Pimple, A. Babbar, R. Mathur, A. Mishra, and R. Murthy, Investigation on design of stable etoposide-loaded PEG-PCL micelles: Effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles. Drug Deliv. 19, 155 (2012).
11. K. V. Pinheiro, V. T. Hungria, E. S. Ficker, C. J. Valduga, C. H. Mesquita, and R. C. Maranhao, Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother. Pharmacol. 57, 624 (2006).
12. I. Ali, U. Rahis, K. Salim, M. A. Rather, W. A. Wani, and A. Haque, Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 11, 135 (2011).
13. J. Shaikh, D. D. Ankola, V. Beniwal, D. Singh, and M. N. Kumar, Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37, 223 (2009).
14. G. Swarnkar, K. Sharan, J. A. Siddiqui, J. S. Mishra, K. Khan, M. P. Khan, V. Gupta, P. Rawat, R. Maurya, A. K. Dwivedi, S. Sanyal, and N. Chattopadhyay, A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br. J. Pharmacol. 165, 1526.
15. P. Dixit, R. Chillara, V. Khedgikar, J. Gautam, P. Kushwaha, A. Kumar, D. Singh, R. Trivedi, and R. Maurya, Constituents of dalbergia sissoo roxb. leaves with osteogenic activity. Bioorg. Med. Chem. Lett. 22, 890.
16. A. L. Hilchie, S. J. Furlong, K. Sutton, A. Richardson, M. R. Robichaud, C. A. Giacomantonio, N. D. Ridgway, and D. W. Hoskin, Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr. Cancer 62, 379 (2010).
17. A. Mukhopadhyay, C. Bueso-Ramos, D. Chatterjee, P. Pantazis, and B. B. Aggarwal, Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20, 7597 (2001).
18. A. A. Date and M. S. Nagarsenker, Parenteral microemulsions: An overview. International Journal of Pharmaceutics 355, 19 (2008).
19. P. P. Constantinides, A. Tustian, and D. R. Kessler, Tocol emulsions for drug solubilization and parenteral delivery. Advanced Drug Delivery Reviews 56, 1243 (2004).
20. C. L. Yang, Y. Y. Liu, Y. G. Ma, Y. X. Xue, D. G. Liu, Y. Ren, X. B. Liu, Y. Li, and Z. Li, Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through janus kinase-STAT3 signalling pathway. PLoS One7, e37960 (2012).
21. L. Hu, Y. Jia, F. Niu, Z. Jia, X. Yang, and K. Jiao, Preparation and enhancement of oral bioavailability of curcumin using microemulsion vehicle. Journal of Agricultural and Food Chemistry 60, 7137 (2012).
22. X. Ren, D. Svirskis, R. G. Alany, S. Zargar-Shoshtari, and Z. Wu, In-situ phase transition from microemulsion to liquid crystal with the potential of prolonged parenteral drug delivery. International Journal of Pharmaceutics 431, 130 (2012).
23. N. Rodríguez-Hornedo and D. Murphy, Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. Journal of Pharmaceutical Sciences 88, 651 (1999).
24. G. K. Gupta, V. K. Gupta, P. Shukla, A. B. Pant, and P. R. Mishra, Investigations on cellular interaction of polyelectrolyte based nanowalled reservoir using MCF-7 cell lines: A novel chemotherapeutic approach. Journal of Pharmacy and Pharmacology 61, 1601 (2009).
25. G. Sardana, K. Jung, C. Stephan, and E. P. Diamandis, Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: Discovery and validation of candidate prostate cancer biomarkers. Journal of Proteome Research 7, 3329 (2008).
26. V. Khedgikar, P. Kushwaha, J. Gautam, A. Verma, B. Changkija, A. Kumar, S. Sharma, G. Nagar, D. Singh, and P. Trivedi, Withaferin A: A proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death and Disease 4, e778 (2013).
27. I. V. Litvinov, L. Antony, S. L. Dalrymple, R. Becker, L. Cheng, and J. T. Isaacs, PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. The Prostate 66, 1329 (2006).
28. J. Guo, T. Zhu, L. Chen, T. Nishioka, T. Tsuji, Z. X. Xiao, and C. Y. Chen, Differential sensitization of different prostate cancer cells to apoptosis. Genes Cancer 1, 836 (2010).
29. S. Basu, K. R. Rosenzweig, M. Youmell, and B. D. Price, The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage. Biochem. Biophys. Res. Commun. 247, 79 (1998).
30. R. N. Kaplan, B. Psaila, and D. Lyden, Bone marrow cells in the 'pre-metastatic niche:' Within bone and beyond. Cancer Metastasis Rev. 25, 521 (2006).
31. K. Tantivejkul, L. M. Kalikin, and K. J. Pienta, Dynamic process of prostate cancer metastasis to bone. J. Cell Biochem. 91, 706 (2004).
32. J. Quan, C. Zhou, N. W. Johnson, G. Francis, J. E. Dahlstrom, and J. Gao, Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. Pathology-Journal of the RCPA 44, 221 (2012).
33. A. Halbersztadt, A. Halon, J. Pajak, J. Robaczynski, J. Rabczynski, and M. St. Gabrys [The role of matrix metalloproteinases in tumor invasion and metastasis]. Ginekol Pol. 77, 63 (2006).
34. E. I. Deryugina and J. P. Quigley, Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9 (2006).
35. J. F. Santibanez, S. Silva, and J. Martinez, Soluble factors produced by PC-3 prostate cells decrease collagen content and mineralisation rate in fetal rat osteoblasts in culture. British Journal of Cancer 74, 418 (1996).
36. J. Martinez, S. Silva, and J. F. Santibanez, Prostate-derived soluble factors block osteoblast differentiation in culture. J. Cell Biochem. 61, 18 (1996).